CD274 and neoplasm: In one study, pembrolizumab in combination with bevacizumab was ineffective in prolonging overall survival or progression free survival, and no tumor immune biomarkers that were collected (including tumor PD-L1 expression, tumor-infiltrating lymphocyte density, immune activation gene expression signature, and plasma cytokines) predicted outcomes (148).